What are the indications, recommended dosing, contraindications, and common adverse effects of telmisartan?

Telmisartan: Clinical Overview

Telmisartan is an angiotensin II receptor blocker (ARB) indicated for hypertension treatment (starting dose 40 mg once daily, range 20-80 mg) and cardiovascular risk reduction in high-risk patients ≥55 years unable to take ACE inhibitors (80 mg once daily), with contraindications including pregnancy, known hypersensitivity, and co-administration with aliskiren in diabetic patients. 1

Indications

• Hypertension treatment: To lower blood pressure as monotherapy or in combination with other antihypertensive agents, reducing risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions 1

• Cardiovascular risk reduction: For patients ≥55 years at high risk of major cardiovascular events (history of coronary artery disease, peripheral arterial disease, stroke, TIA, or high-risk diabetes with end-organ damage) who are unable to take ACE inhibitors 1

Dosing Recommendations

Hypertension 1

• Starting dose: 40 mg once daily
• Dose range: 20-80 mg once daily
• Timing: May be administered with or without food
• Response timeline: Most antihypertensive effect apparent within 2 weeks; maximal reduction generally attained after 4 weeks 1
• Special populations: No initial dosage adjustment necessary for elderly patients or those with renal impairment, including hemodialysis patients (though monitor closely for orthostatic hypotension) 1

Cardiovascular Risk Reduction 1

• Dose: 80 mg once daily (only dose proven effective for this indication)
• Monitoring: Blood pressure monitoring recommended when initiating therapy; adjust other BP-lowering medications as appropriate 1

Guideline-Based Context

• Telmisartan is recognized as a first-line antihypertensive agent alongside other ARBs, ACE inhibitors, dihydropyridine calcium channel blockers, and thiazide/thiazide-like diuretics 2, 3
• Combination therapy is recommended for most patients with confirmed hypertension (BP ≥140/90 mmHg), preferably with a RAS blocker plus a dihydropyridine CCB or diuretic 3

Contraindications

• Absolute contraindications 1:

  • Known hypersensitivity (anaphylaxis or angioedema) to telmisartan or any component
  • Co-administration with aliskiren in patients with diabetes
  • Pregnancy (when detected, discontinue immediately)

• Avoid combining 2, 3:

  • Do not combine two RAS blockers (ACE inhibitor + ARB)
  • Use with ACE inhibitor is not recommended 1

Warnings and Precautions

Fetal Toxicity 1

• Black Box Warning: Drugs acting on the renin-angiotensin system cause fetal injury and death during second and third trimesters
• Discontinue telmisartan as soon as pregnancy is detected
• Can cause oligohydramnios, fetal lung hypoplasia, skeletal deformations, skull hypoplasia, anuria, hypotension, renal failure, and death

Hypotension 1

• Symptomatic hypotension may occur in volume- or salt-depleted patients (e.g., those on high-dose diuretics)
• Correct volume/salt depletion before initiating therapy or start under close supervision with reduced dose
• Transient hypotensive response is not a contraindication to continued treatment

Hyperkalemia 1

• Risk particularly in patients with advanced renal impairment, heart failure, renal replacement therapy, or those on potassium supplements, potassium-sparing diuretics, or potassium-containing salt substitutes
• Consider periodic serum electrolyte monitoring in at-risk patients

Hepatic Impairment 1

• Majority of telmisartan eliminated by biliary excretion
• Patients with biliary obstructive disorders or hepatic insufficiency have reduced clearance
• Initiate at low doses and titrate slowly

Renal Impairment 1

• May cause changes in renal function in susceptible individuals whose renal function depends on renin-angiotensin-aldosterone system activity
• Risk of oliguria, progressive azotemia, acute renal failure (rare), particularly in severe congestive heart failure or renal dysfunction

Adverse Effects

Common Adverse Events (≥1%) 1

• Hypertension trials: Back pain, sinusitis, diarrhea
• Cardiovascular risk reduction trials: Intermittent claudication, skin ulcer (serious adverse events)

Tolerability Profile

• Overall tolerability similar to placebo 4, 5, 6
• Significantly lower incidence of persistent dry cough compared to ACE inhibitors (lisinopril) 4, 7
• No drug-related serious adverse events in isolated systolic hypertension study 8

Drug Interactions 1

• NSAIDs: Increased risk of renal impairment and loss of antihypertensive effect
• Aliskiren: Do not co-administer in patients with diabetes (contraindicated)
• Diltiazem and verapamil: CYP3A4 interactions (though telmisartan itself has minimal CYP metabolism)

Clinical Efficacy Highlights

• 24-hour BP control: Long elimination half-life ensures effective BP reduction across entire dosage interval, including last 6 hours 7, 5
• Comparative efficacy: Superior to losartan 50 mg and valsartan 80 mg at telmisartan 80 mg dose; comparable to enalapril, lisinopril, amlodipine, and atenolol at appropriate doses 4, 6
• Isolated systolic hypertension: All doses (20-80 mg) significantly superior to placebo; 80 mg achieved target SBP in 53.9% of patients 8
• Additional metabolic benefits: Favorable effects on insulin resistance, lipid levels, left ventricular hypertrophy, and renal function independent of BP effects 7, 9

Special Populations

• Elderly: No overall difference in efficacy or safety versus younger patients 1
• Lactation: Do not breastfeed during treatment 1
• Hemodialysis: May develop orthostatic hypotension; monitor BP closely 1